SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Coherus Oncology, Inc. (CHRS) News

Follow Coherus Oncology, Inc. (CHRS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CHRS Asset equity Sector Markets 90 days 13 Last 0.3713 Updated Nov 09, 2026, 09:29 PM UTC Open live news feed Open CHRS chart & news
M Coherus Oncology Q3 Sales Were $14.274 Million Q3 net income was reported as a loss. IBES estimated sales at $16 million. EARNINGS | Nov 09, 2026, 09:29 PM UTC M Coherus Reports 89% Confirmed Response Rate in Esophageal Cancer Trial Coherus Oncology reported an 89% confirmed response rate for a tagmokitug combination in a first-line esophageal cancer trial. EQUITY | Oct 29, 2026, 12:21 PM UTC M Coherus Reports 75% Tagmokitug Response Rate in First-Line ESCC Coherus Oncology reported a 75% confirmed response rate among evaluable first-line ESCC patients, rising to 89% after the data cutoff. The company plans to expand the cohort. EQUITY | Oct 29, 2026, 12:13 PM UTC M Coherus Oncology to Report Third-Quarter 2026 Results on November 9 EQUITY | Oct 26, 2026, 01:30 PM UTC L Coherus Oncology Initiates Process To Sell Legacy Biosim Assets Coherus Oncology Inc NASDAQ:CHRS NEWS | Sep 23, 2026, 02:16 PM UTC L Coherus Oncology, Inc. (CHRS) Hires Oppenheimer to Sell Legacy Biosim Assets; CVRs in Place Coherus Oncology retained Oppenheimer to market and sell its legacy biosimilar assets. Holders of CVRs, to be distributed to stockholders of record on Sept. 30, 2026, will receive their pro rata share of any net proceeds NEWS | Sep 23, 2026, 01:32 PM UTC L Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. NASDAQ:CHRS today announced that it has initiated NEWS | Sep 23, 2026, 01:32 PM UTC L CHRS - Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets CHRS - Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets NEWS | Sep 23, 2026, 01:30 PM UTC L CHRS: Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end The company has fully transitioned to innovative oncology, with LOQTORZI driving revenue growth and funding a robust pipeline. Key assets tagmokitug and casdozokitug are advancing in trials, with major data updates expec EARNINGS | Sep 15, 2026, 05:00 PM UTC L CHRS: Strategic oncology focus drives revenue growth and key clinical milestones, with major data readouts ahead A completed pivot to innovative oncology has positioned the company as both a commercial and clinical stage player, with LOQTORZI driving revenue and funding pipeline development. Key data readouts for tagmokitug and cas EARNINGS | Sep 15, 2026, 04:32 PM UTC L CHRS: Pipeline advances and strong LOQTORZI sales position for growth, with major data readouts ahead The conference highlighted a robust oncology pipeline focused on immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple cancer indications. Key data readouts and EARNINGS | Sep 15, 2026, 01:24 PM UTC L CHRS: Pipeline advances and commercial execution position for growth, with major data readouts ahead The conference highlighted a robust oncology pipeline targeting immune resistance, with LOQTORZI driving commercial growth and tagmokitug and casdozokitug advancing in multiple indications. Key data readouts are expected EARNINGS | Sep 15, 2026, 12:48 PM UTC L Coherus Oncology files $50M at-the-market sales agreement Coherus Oncology filed a $50M at-the-market sales agreement with Leerink Partners. EQUITY | Aug 28, 2026, 09:14 PM UTC L Coherus Oncology unveils CVR dividend, starts biosimilar asset sale Coherus Oncology said it will distribute a special dividend of contingent value rights to common stockholders of record on September 30, 2026 and immediately commence a sale process for its legacy biosimilar assets. EARNINGS | Aug 17, 2026, 09:37 PM UTC L CHRS - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update CHRS - Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update EARNINGS | Aug 05, 2026, 08:28 PM UTC